ArticleEye (London, England)2026
Association of baseline brain care score with the incidence of age-related eye diseases.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo evaluate the associations of baseline brain care score (BCS) with the incidence of age-related eye diseases (AREDs), and to examine the modifying effects of age and genetic susceptibility.
methodsWe included 382,221 UK Biobank participants without cataract, glaucoma, or age-related macular degeneration (AMD) at baseline. Baseline BCS (0-19 point) encompassed physical, lifestyle and social-emotional factors. Higher BCS scores indicated better brain care. Multivariable Cox regression was used to estimate associations between baseline BCS and incident cataract, glaucoma, and AMD. Polygenic risk scores (PRSs) were used to test gene-BCS interactions.
resultsOver a median follow-up of 14.28 (interquartile range: 13.34-15.11) years, 44,033 cataract cases, 9280 glaucoma cases, and 6754 AMD cases were identified. Compared with the lowest baseline BCS quintile, the highest baseline BCS quintile was associated with lower risk of cataract (adjusted hazard ratios [HR]: 0.89, 95% confidence interval [CI]: 0.86-0.92), glaucoma (0.92, 0.86-0.98), and AMD (0.90, 0.83-0.97). Stronger associations of per 5-unit increase in baseline BCS with incident cataract (0.78, 0.71-0.85) and glaucoma (0.72, 0.64-0.83) were observed in participants aged 40-50 years than in older groups, with significant interactions with age (P-interaction < 0.001). A significant interaction between baseline BCS and PRS was observed for cataract (P-interaction < 0.001), but not for glaucoma or AMD.
conclusionsHigher baseline BCS is associated with lower long-term risk of AREDs, especially in middle-aged individuals. These findings underscore BCS as a novel and potentially modifiable factor for AREDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.